Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Change in Cash (2022 - 2025)

Historic Change in Cash for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$11.2 million.

  • Atara Biotherapeutics' Change in Cash fell 17372.35% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$40.9 million, marking a year-over-year decrease of 12279.97%. This contributed to the annual value of -$811000.0 for FY2024, which is 9879.14% up from last year.
  • Atara Biotherapeutics' Change in Cash amounted to -$11.2 million in Q3 2025, which was down 17372.35% from $2.9 million recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' Change in Cash peaked at $26.6 million during Q4 2022, and registered a low of -$44.2 million during Q1 2023.
  • Over the past 4 years, Atara Biotherapeutics' median Change in Cash value was -$4.5 million (recorded in 2022), while the average stood at -$6.8 million.
  • Over the last 5 years, Atara Biotherapeutics' Change in Cash had its largest YoY gain of 43894.87% in 2023, and its largest YoY loss of 89038.76% in 2023.
  • Atara Biotherapeutics' Change in Cash (Quarter) stood at $26.6 million in 2022, then plummeted by 246.27% to -$38.9 million in 2023, then soared by 45.0% to -$21.4 million in 2024, then surged by 47.9% to -$11.2 million in 2025.
  • Its Change in Cash stands at -$11.2 million for Q3 2025, versus $2.9 million for Q2 2025 and -$11.2 million for Q1 2025.